Aclarion (ACON) has had the highest return since January 1, 2025 by a US stock in the Nasdaq Composite (IXIC), returning 5,815.5%.
| ASSET | % RETURN |
|---|---|
Aclarion (ACON) | 5,815.49% |
Conduit Pharmaceuticals (CDT) | 3,734.59% |
Wang & Lee Group, Inc Ordinary Shares (WLGS) | 308.05% |
Dominari (DOMH) | 265.31% |
Oncology Institute (TOI) | 230.07% |
Noodles (NDLS) | 140.25% |
Transcode Therapeutics (RNAZ) | 139.58% |
36Kr (KRKR) | 135.84% |
Coeptis Therapeutics (COEP) | 130.4% |
Digihost Technology (DGHI) | 130.19% |
Nvni Group Limited Ordinary Shares (NVNI) | 129.8% |
Boxlight Corp Class A (BOXL) | 125.27% |
Sacks Parente Golf, Inc Common Stock (SPGC) | 114.62% |
Sana Biotechnology (SANA) | 114.11% |
Unity Biotechnology (UBX) | 111.88% |
Rapid Micro Biosystems (RPID) | 109.89% |
Supercom (SPCB) | 107.75% |
Neuronetics (STIM) | 106.67% |
Compass Therapeutics (CMPX) | 101.33% |
Accolade (ACCD) | 98.84% |
Akero Therapeutics (AKRO) | 97.15% |
INmune Bio (INMB) | 94.93% |
Monopar Therapeutics (MNPR) | 93.18% |
Benson Hill, Inc Common Stock (BHIL) | 91.75% |
Elicio Therapeutics (ELTX) | 89.54% |
